Derivation of pharmacophore and CoMFA models for leukotriene D4 receptor antagonists of the quinolinyl(bridged)aryl series

Journal of Medicinal Chemistry

Volumn 43, Issue 3, 2000, Pages 392-400

  Palomer, Albert ^a   Pascual, Jaume ^a   Cabré, Francesc ^a   García, M Lluïsa ^a   Mauleón, David ^a  

^a Laboratorios Menarini   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOTRIENE D4 RECEPTOR; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; QUINOLINE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; CONFORMATION; ENERGY; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR DYNAMICS; MOLECULAR MODEL; NONHUMAN; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

COMBINATORIAL CHEMISTRY TECHNIQUES; LEUKOTRIENE ANTAGONISTS; MEMBRANE PROTEINS; MODELS, MOLECULAR; QUINOLINES; RECEPTORS, LEUKOTRIENE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034628496     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990387k     Document Type: Article

References (50)

1. Borgeat, P.; Samuelsson, B. Metabolism of Arachidonic Acid in Polymorphonuclear Leukocytes: Structural Analysis of Novel Hydroxylated Compounds. J. Biol. Chem. 1979, 254, 7865-1869. Hammarstrom, S.; Murphy, R.; Samuelsson, B.; Clark, D. A.; Mioskowski, C. Ch.; Corey, E. J. Structure of Leukotriene C. Identification of the Amino acid Part. Biochem. Biophys. Res. Commun. 1979, 91, 1266-1268. Borgeat, P.; Samuelsson, B. Arachidonic Acid Metabolism in Polymorphonuclear Leukocytes: Effects of Ionophore A23187. Proc. Natl. Acad. Sci. U.S.A. 1979, 76, 2148-2152. Borgeat, P.; Samuelsson, B. Transformation of Arachidonic Acid by Rabbit Polymorphonuclear Leukocytes: Formation of Novel Dihydroxyeicosatetraenoic Acid. J. Biol. Chem. 1979, 254, 2643-2646.
2. Borgeat, P.; Samuelsson, B. Metabolism of Arachidonic Acid in Polymorphonuclear Leukocytes: Structural Analysis of Novel Hydroxylated Compounds. J. Biol. Chem. 1979, 254, 7865-1869. Hammarstrom, S.; Murphy, R.; Samuelsson, B.; Clark, D. A.; Mioskowski, C. Ch.; Corey, E. J. Structure of Leukotriene C. Identification of the Amino acid Part. Biochem. Biophys. Res. Commun. 1979, 91, 1266-1268. Borgeat, P.; Samuelsson, B. Arachidonic Acid Metabolism in Polymorphonuclear Leukocytes: Effects of Ionophore A23187. Proc. Natl. Acad. Sci. U.S.A. 1979, 76, 2148-2152. Borgeat, P.; Samuelsson, B. Transformation of Arachidonic Acid by Rabbit Polymorphonuclear Leukocytes: Formation of Novel Dihydroxyeicosatetraenoic Acid. J. Biol. Chem. 1979, 254, 2643-2646.
3. Borgeat, P.; Samuelsson, B. Metabolism of Arachidonic Acid in Polymorphonuclear Leukocytes: Structural Analysis of Novel Hydroxylated Compounds. J. Biol. Chem. 1979, 254, 7865-1869. Hammarstrom, S.; Murphy, R.; Samuelsson, B.; Clark, D. A.; Mioskowski, C. Ch.; Corey, E. J. Structure of Leukotriene C. Identification of the Amino acid Part. Biochem. Biophys. Res. Commun. 1979, 91, 1266-1268. Borgeat, P.; Samuelsson, B. Arachidonic Acid Metabolism in Polymorphonuclear Leukocytes: Effects of Ionophore A23187. Proc. Natl. Acad. Sci. U.S.A. 1979, 76, 2148-2152. Borgeat, P.; Samuelsson, B. Transformation of Arachidonic Acid by Rabbit Polymorphonuclear Leukocytes: Formation of Novel Dihydroxyeicosatetraenoic Acid. J. Biol. Chem. 1979, 254, 2643-2646.
4. Borgeat, P.; Samuelsson, B. Metabolism of Arachidonic Acid in Polymorphonuclear Leukocytes: Structural Analysis of Novel Hydroxylated Compounds. J. Biol. Chem. 1979, 254, 7865-1869. Hammarstrom, S.; Murphy, R.; Samuelsson, B.; Clark, D. A.; Mioskowski, C. Ch.; Corey, E. J. Structure of Leukotriene C. Identification of the Amino acid Part. Biochem. Biophys. Res. Commun. 1979, 91, 1266-1268. Borgeat, P.; Samuelsson, B. Arachidonic Acid Metabolism in Polymorphonuclear Leukocytes: Effects of Ionophore A23187. Proc. Natl. Acad. Sci. U.S.A. 1979, 76, 2148-2152. Borgeat, P.; Samuelsson, B. Transformation of Arachidonic Acid by Rabbit Polymorphonuclear Leukocytes: Formation of Novel Dihydroxyeicosatetraenoic Acid. J. Biol. Chem. 1979, 254, 2643-2646.
5. Fort-Hutchinson, A. W. Leukotriene Antagonists and Inhibitors: Clinical Applications. Adv. Prostaglandin, Thromboxane, Leukotriene Res. 1995, 23, 69-74.
6. Larsen, J. S.; Acosta, E. P. Leukotriene-Receptor Antagonists and 5-Lipoxygenase Inhibitors in Asthma. Ann. Pharmacother. 1993, 27, 898-903.
7. Chung, K. F. Leukotriene Receptor Antagonists and Biosynthesis Inhibitors: Potential Breakthrough in Asthma Therapy. Eur. Respir. J. 1995, 8, 1203-1213.
8. Pauwels, R. A.; Joos, G. F.; Kips, J. C. Leukotrienes as Therapeutic Target in Asthma. Allergy 1995, 50, 615-622.
9. Taylor, I. K. Cysteinyl Leukotrienes in Asthma: Current State of Therapeutic Evaluation. Thorax 1995, 50, 1005-1010.
10. Smith, L. J. Leukotrienes in Asthma: the Potentials Therapeutic Role of Antileukotriene Agents. Arch. Intern. Med. 1996, 156, 2181-2189.
11. Barnes, N. Leukotriene Receptor Antagonists: Clinical Effects. J. R. Soc. Med. 1997, 90, 200-204.
12. Nicosia, S.; Capra, V.; Giovanazzi, S.; Rovati, E. Binding Sites for Peptido-Leukotrienes in Human Lung Parenchyma. In Int. Acad. Biomed. Drug Res.; Langer, S. Z., Church, M. K., Nicosia, S., Eds.; Karger: Basel, 1993; Vol. 6, pp 86-90.
13. Nicosia, S.; Capra, V.; Ragnini, D.; Giovanazzi, S.; Mezzeti, M.; Kepler, D.; Müller, M.; Rovati, G. E. Receptors for Cysteinyl Leukotrienes in Human Lung Parenchyma: Characterization by Computer Modelling and Photoaffinity Labeling of Binding Sites. In Advances in Prostaglandin, Thromboxane and Leukotriene Research; Samuelsson, B., Ed.; Raven Press Ltd.: New York, 1995; pp 267-269. Capra, V.; Rovati, G. E.; Bianchi, M.; Mezzeti, M.; Nicosia, S. Computer Analysis of a Possible Model for Cysteinyl Leukotrienes Receptors in Human Lung Membranes. Br, J. Pharmacol. 1994, 111 (Suppl.), Abstr. 324p.
14. Nicosia, S.; Capra, V.; Ragnini, D.; Giovanazzi, S.; Mezzeti, M.; Kepler, D.; Müller, M.; Rovati, G. E. Receptors for Cysteinyl Leukotrienes in Human Lung Parenchyma: Characterization by Computer Modelling and Photoaffinity Labeling of Binding Sites. In Advances in Prostaglandin, Thromboxane and Leukotriene Research; Samuelsson, B., Ed.; Raven Press Ltd.: New York, 1995; pp 267-269. Capra, V.; Rovati, G. E.; Bianchi, M.; Mezzeti, M.; Nicosia, S. Computer Analysis of a Possible Model for Cysteinyl Leukotrienes Receptors in Human Lung Membranes. Br, J. Pharmacol. 1994, 111 (Suppl.), Abstr. 324p.
15. Nicosia, S. Pharmacological Characteristics of Leukotriene Antagonists. Monaldi Arch. Chest. Dis. 1996, 51, 556-564.
16. 1 Receptors of Guinea Pig Lung. Bioorg. Med. Chem. Lett. 1997, 7, 1331-1336.
17. Terada, H.; Goto, S.; Hori, H.; Taira, Z. In QSAR and Drug Design - New Developments and Applications; Fujita, T., Ed.; 1995; pp 341-367. Hermann, R. B.; Herron, D. K. OVID and SUPER: Two Overlap Programs for Drug Design. J. Comput.-Aided Mol. Des. 1991, 5, 511-524.
18. Terada, H.; Goto, S.; Hori, H.; Taira, Z. In QSAR and Drug Design - New Developments and Applications; Fujita, T., Ed.; 1995; pp 341-367. Hermann, R. B.; Herron, D. K. OVID and SUPER: Two Overlap Programs for Drug Design. J. Comput.-Aided Mol. Des. 1991, 5, 511-524.
19. 4 Receptor Antagonism. XIth European Symposium on Structure-Activity Relationships: Computer-Assisted Lead Finding and Optimization, Laussanne, 1996; P70D.
20. 4 Receptor Antagonism. XIth European Symposium on Structure-Activity Relationships: Computer-Assisted Lead Finding and Optimization, Laussanne, 1996; P70D.
21. Hariprasad, V.; Kulkarni, V. M. A Proposed Common Spatial Pharmacophore and the Corresponding Active Conformations of Some Peptide Leukotriene Receptor Antagonists. J. Comput.-Aided Mol. Des. 1996, 10, 284-292.
22. 4) Antagonist Model with an Incorporated Amino Acid Residue from the Receptor. J. Med. Chem. 1998, 41, 1439-1445.
23. 4) Antagonist Model with an Incorporated Amino Acid Residue from the Receptor. J. Med. Chem. 1998, 41, 1439-1445.
24. 2 Receptor. Bioorg. Med. Chem. Lett. 1995, 5, 283-289.
25. 4 Receptor Binding Affinity. J. Med. Chem. 1991, 34, 1704-1709.
26. Kirstein, D.; Neilson, C. K.; Bramm, E. OT-4003 a Potent Long-acting Orally Active Leukotriene D4 Receptor Antagonist. Inflamm. Res. 1995, 44 (Suppl. 3), S261 (Abstr. W11/20).
27. 4 Antagonists. XIVth International Symposium in Medicinal Chemistry, Maastricht, 1996; P230.
28. 4 Antagonists. XIVth International Symposium in Medicinal Chemistry, Maastricht, 1996; P230.
29. Cramer III, R. D.; Patterson, D. E.; Bunce, J. D. Comparative Molecular Field Analysis (CoMFA) Effect of Shapes on Binding of Steroids to Proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
30. Martin, Y. C.; Lin, C. T.; Wy, L. Application of CoMFA to D1 Dopaminergic Agonists: A Case Study. In 3D QSAR in Drug Design; Kubinyi, H., Ed.; ESCOM: Leiden, 1993; pp 643-660.
31. Klebe, G.; Abraham, U. On the Prediction of Binding Properties of Drug Molecules by Comparative Molcular Field Analysis. J. Med. Chem. 1993, 36, 70-80.
32. Mattos, C.; Ringe, D. Multiple Binding Modes. In 3D QSAR in Drug Design; Kubinyi, H., Ed.; ESCOM: Leiden, 1993; pp 226-254.
33. Marshall, G. R.; Barry, C. D.; Bosshard, H. E.; Dammkoehler, R. A.; Dunn, D. A. A Conformational Parameter in Drug Design: The Active Analogue Approach. ACS Symp. Series 1979, 112, 205-226.
34. Martin, Y. C.; Bures, M. G.; Danaher, E. A.; DeLazzer, J. New Strategies that Improve the Efficiency of the 3D Design of Bioactive Molecules. In Trends in QSAR and Molecular Modelling 92; Wermuth, C., Ed.; ESCOM: Leiden, 1993; pp 20-26.
35. Oprea, T. I.; Waller, C. L.; Marshall, G. R. Three-dimensional Quantitative Structre Activity Relationship of Human HIV (I) Protease Inhibitors. 2. Predictive Power Using Limited Exploration of Alternate Binding Sites. J. Med. Chem. 1994, 37, 2206-2012.
36. Nicklaus, M. C.; Milne, G. W. A.; Burke, T. R. QSAR of Conformationally Flexible Molecules: CoMFA of Protein-Tyrosine Kinase Inhibitors. J. Comput.-Aided Mol. Des. 1992, 6, 487-504.
37. 4 Receptor Antagonists: LM-1426, LM-1453 and LM-1468. Prostagl. Leukotr., Essent. Fatty Acids 1996, 55, 104.
38. 4 Receptor Antagonists: LM-1426, LM-1453 and LM-1468. Prostagl. Leukotr., Essent. Fatty Acids 1996, 55, 104.
39. Sprague, P. W. Automated Chemical Hypothesis Generation and Database Searching with Catalyst. In Perspectives in Drug Discovery and Design; Müller, K., Ed.; ESCOM, Leiden, 1995; pp 1-20. Kaminski, J. J.; Rane, D. F.; Snow, M. E.; Weber, L.; Rothofsky M. L.; Anderson, S. D.; Lin, S. L. Identification of Novel Farnesyl Protein Transferase Inhibitors Using Three-Dimensional Database Searching Methods. J. Med. Chem. 1997, 40, 4103-4112. Keller, P.; Bowman, M.; Dang, K. H.; Garner, J.; Leach, S. P.; Smith, R.; McCluskey, A. Pharmacophore Development for Corticotropin-Releasing Hormone: New Insights into Inhibitor Activity. J. Med. Chem. 1999, 42, 2351-2357.
40. Sprague, P. W. Automated Chemical Hypothesis Generation and Database Searching with Catalyst. In Perspectives in Drug Discovery and Design; Müller, K., Ed.; ESCOM, Leiden, 1995; pp 1-20. Kaminski, J. J.; Rane, D. F.; Snow, M. E.; Weber, L.; Rothofsky M. L.; Anderson, S. D.; Lin, S. L. Identification of Novel Farnesyl Protein Transferase Inhibitors Using Three-Dimensional Database Searching Methods. J. Med. Chem. 1997, 40, 4103-4112. Keller, P.; Bowman, M.; Dang, K. H.; Garner, J.; Leach, S. P.; Smith, R.; McCluskey, A. Pharmacophore Development for Corticotropin-Releasing Hormone: New Insights into Inhibitor Activity. J. Med. Chem. 1999, 42, 2351-2357.
41. Sprague, P. W. Automated Chemical Hypothesis Generation and Database Searching with Catalyst. In Perspectives in Drug Discovery and Design; Müller, K., Ed.; ESCOM, Leiden, 1995; pp 1-20. Kaminski, J. J.; Rane, D. F.; Snow, M. E.; Weber, L.; Rothofsky M. L.; Anderson, S. D.; Lin, S. L. Identification of Novel Farnesyl Protein Transferase Inhibitors Using Three-Dimensional Database Searching Methods. J. Med. Chem. 1997, 40, 4103-4112. Keller, P.; Bowman, M.; Dang, K. H.; Garner, J.; Leach, S. P.; Smith, R.; McCluskey, A. Pharmacophore Development for Corticotropin-Releasing Hormone: New Insights into Inhibitor Activity. J. Med. Chem. 1999, 42, 2351-2357.
42. Catalyst version 2.2, Molecular Simulations Inc., San Diego, CA.
43. Greene, J.; Kahn, S.; Savoj, H.; Sprague, P.; Teig, S. Chemical Function Queries for 3D Database Search. J. Chem. Inf. Comput. Sci. 1994, 34, 1297-1308.
44. Masamune, H.; Eggler, J. F.; Marfat, A.; Melvin, L. S.; Rusek, F. W.; Tickner, J. E.; Cheng, J. B.; Shirley, J. T. LTD(4) receptor binding activity of novel pyridine chromanols: Qualitative correlation with pK(a). Bioorg. Med. Chem. Lett. 1995, 5 (13), 1371-1376.
45. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMm: A Program for Macromolecular Energy, Minimization and Dynamics Calculations. J. Comput. Chem. 1983, 4, 187-196.
46. Smellie, A. S.; Teig, S. L.; Towbin, P. Poling: Promoting Conformational Variation. J. Comput Chem. 1995, 16, 171-176.
47. Smellie, A. S.; Kahn, S. D.; Teig, S. L. Analysis of Conformational Coverage. 1. Validation and Estimation of Coverage. J. Chem. Inf. Comput. Sci. 1995, 35, 285-292.
48. Smellie, A. S.; Kahn, S. D.; Teig, S. L. Analysis of Conformational Coverage. 2. Application of Conformatinal Models. J. Chem. Inf. Comput. Sci. 1995, 35, 295-301.
49. Thibaut, U.; Folkers, G.; Klebe, G.; Kubinyi, H.; Merz, A.; Rognan, D. Recommendations for CoMFA Studies and 3D QSAR Publications. In 3D QSAR in Drug Design; Kubinyi, H., Ed.; ESCOM: Leiden, 1993; pp 711-716. Thibaut, U.; Folkers, G.; Klebe, G.; Kubinyi, H.; Merz, A.; Rognan, D. Recommendations for CoMFA Studies and 3D QSAR Publications. Quant. Struct.-Act. Relat. 1994, 13, 1-3.
50. Thibaut, U.; Folkers, G.; Klebe, G.; Kubinyi, H.; Merz, A.; Rognan, D. Recommendations for CoMFA Studies and 3D QSAR Publications. In 3D QSAR in Drug Design; Kubinyi, H., Ed.; ESCOM: Leiden, 1993; pp 711-716. Thibaut, U.; Folkers, G.; Klebe, G.; Kubinyi, H.; Merz, A.; Rognan, D. Recommendations for CoMFA Studies and 3D QSAR Publications. Quant. Struct.-Act. Relat. 1994, 13, 1-3.